Personal information

No personal information available

Activities

Employment (1)

The Ohio State University Wexner Medical Center: Columbus, Ohio, US

2017-07-01 to present | Assistant Professor (Medical Oncology)
Employment
Source: Self-asserted source
Ming Yin

Education and qualifications (1)

Penn State Milton S. Hershey Medical Center: Hershey, Pennsylvania, US

2014-07-01 to 2017-06-30 (Hematology and Oncology Fellowship)
Education
Source: Self-asserted source
Ming Yin

Professional activities (1)

American Society of Clinical Oncology: Alexandria, VA, US

2014-07-01 to present | Full Member
Membership
Source: Self-asserted source
Ming Yin

Works (5)

Low Dose Enzalutamide in Metastatic Prostate Cancer - Longevity over Conventional Survival Analysis

Clinical Genitourinary Cancer
2022-06 | Journal article
Contributors: Vincent Vinh-Hung; Olena Gorobets; Gilles Natchagande; Paul Sargos; Ming Yin; Nam P. Nguyen; Claire Verschraegen; Edmund Folefac
Source: check_circle
Crossref

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis

Cancer Medicine
2022-04 | Journal article
Contributors: Yuanquan Yang; Sherry V. Mori; Mingjia Li; Megan Hinkley; Anish B. Parikh; Katharine A. Collier; Abdul Miah; Ming Yin
Source: check_circle
Crossref

Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer

Cancer Medicine
2020-12 | Journal article
Contributors: Monika Joshi; Petros Grivas; Amir Mortazavi; Paul Monk; Steven K. Clinton; Michele Sue‐Ann Woo; Sheldon L. Holder; Joseph J. Drabick; Ming Yin
Source: check_circle
Crossref

Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high‐risk localized prostate cancer

Cancer Medicine
2020-01 | Journal article
Contributors: Ming Yin; Jing Zhao; Paul Monk; Douglas Martin; Edmund Folefac; Monika Joshi; Ning Jin; Amir Mortazavi; Claire Verschraegen; Steven Clinton
Source: check_circle
Crossref

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research
2011-01-28 | Journal article
Source: Self-asserted source
Ming Yin